Login to Your Account



INCREASINGLY 'ENDEAR'-ING

Ionis/Akcea tie $1.6B knot; CV bid with Novartis adds to better spin on Spinraza

By Randy Osborne
Staff Writer

Friday, February 17, 2017

With a pair of drugs devoted to what Ionis Pharmaceuticals Inc. CEO Stanley Crooke called "systematically knocking off the remaining lipid risk factors" for patients facing cardiovascular (CV) trouble, the company and its subsidiary, Akcea Therapeutics, closed their potential $1.6 billion deal with Novartis AG.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription